Business Description
Intech Biopharm Ltd
ISIN : TW0006461007
Description
Intech Biopharm Ltd is a biotechnology company. The company develops inhalation products including single or combination generic products and some new combinations or new formulation projects are under development. It develops drugs for the treatment of lung diseases such as asthma.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.42 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 1.23 | |||||
| Debt-to-EBITDA | -6.54 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.96 | |||||
| Beneish M-Score | -2.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.8 | |||||
| 3-Year EBITDA Growth Rate | -8.3 | |||||
| 3-Year EPS without NRI Growth Rate | -4.9 | |||||
| 3-Year FCF Growth Rate | 2.2 | |||||
| 3-Year Book Growth Rate | -12.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.03 | |||||
| 9-Day RSI | 45.82 | |||||
| 14-Day RSI | 45.48 | |||||
| 6-1 Month Momentum % | 9.02 | |||||
| 12-1 Month Momentum % | -16.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | |||||
| Quick Ratio | 1.15 | |||||
| Cash Ratio | 1.05 | |||||
| Days Inventory | 78.79 | |||||
| Days Sales Outstanding | 48.3 | |||||
| Days Payable | 4.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.7 | |||||
| Shareholder Yield % | -5.28 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -634.48 | |||||
| Operating Margin % | -1239.87 | |||||
| Net Margin % | -1307.65 | |||||
| FCF Margin % | -906.64 | |||||
| ROE % | -34.97 | |||||
| ROA % | -13.31 | |||||
| ROIC % | -12.79 | |||||
| ROC (Joel Greenblatt) % | -15.48 | |||||
| ROCE % | -14.82 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 131.61 | |||||
| PB Ratio | 3.29 | |||||
| Price-to-Tangible-Book | 3.3 | |||||
| EV-to-EBIT | -15.34 | |||||
| EV-to-EBITDA | -21.27 | |||||
| EV-to-Revenue | 180.7 | |||||
| EV-to-FCF | -20.19 | |||||
| Earnings Yield (Greenblatt) % | -6.51 | |||||
| FCF Yield % | -6.12 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers